Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 12/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931973 | 0.91 | CXCR2 (0.71) | CXCR2KDM4EMRGPRX4ERAP1NPC1 | |
| SCHEMBL3923114 | 0.90 | CXCR2 (0.70) | CXCR2KDM4EPPARAMEN1NPC1 | |
| SCHEMBL3934004 | 0.86 | CXCR2 (0.67) | CXCR2KDM4EMEN1NPC1RAB9A | |
| SCHEMBL3936425 | 0.84 | CXCR2 (0.76) | CXCR2KDM4EMEN1KMT2A | |
| SCHEMBL3936523 | 0.84 | CXCR2 (0.72) | CXCR2KDM4EERAP1MEN1KMT2A | |
| SCHEMBL3930500 | 0.84 | CXCR2 (0.75) | CXCR2KDM4EMEN1KMT2A | |
| SCHEMBL3923083 | 0.84 | CXCR2 (0.75) | CXCR2KDM4EERAP1 | |
| SCHEMBL3922469 | 0.83 | CXCR2 (0.63) | CXCR2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3924903 | 0.83 | CXCR2 (1.00) | CXCR2KDM4EERAP1 | |
| SCHEMBL3928310 | 0.83 | CXCR2 (0.77) | CXCR2KDM4EERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | claimed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | claimed |
| EP-2040688-A1 | NEW CXCR2 INHIBITORS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | claimed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | claimed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| EP-2040688-A1 | NEW CXCR2 INHIBITORS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227625-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885KDM4E 3853/4885MRGPRX4 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.